From the Journals

AF Stroke Prevention: Testing Ablation

In the randomized STABLED trial, adding catheter ablation to edoxaban did not reduce recurrent stroke or major cardiovascular outcomes.

Share

A randomized clinical trial published in JAMA Neurology evaluated the efficacy of adding catheter ablation to anticoagulation therapy in patients with atrial fibrillation who had experienced a recent ischemic stroke. The STABLED trial involved 251 Japanese patients and found no significant reduction in recurrent stroke or major cardiovascular outcomes when catheter ablation was combined with the factor Xa inhibitor edoxaban. The primary and secondary outcomes did not show meaningful differences, leading to the conclusion that catheter ablation may not provide clear clinical benefits for this patient group.

Original Source(s)

AF Stroke Prevention: Testing Ablation

  • by Kathryn Wighton

  • March 16, 2026

Related Content

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

Dual-drug therapy showed signals of slower disease progression and reduced complications in patients with ALS.

Aneurysmal Hemorrhage Triggers Systemic Effects

Researchers examine physiologic responses following rupture and link them to outcomes.

Physician Burnout: How a Neurocritical Care/Stroke Physician Manages Work-Life Balance

May A. Kim-Tenser, MD, MHA, a neurointensivist/vascular neurologist shares her tips for combatting physician burnout.

  • by

  • March 16, 2026

  • 7 min